Atomo Diagnostics is a medical device manufacturer headquartered in Sydney, Australia with offices in South Africa and the United Kingdom.
Atomo Diagnostics was established to capitalise on a core belief that healthcare products offering significantly improved levels of convenience, simplicity and user experience are disproportionately disruptive and have the potential to be very successful commercial market entrants.
In 2013, Atomo introduced AtomoRapid, a range of safe, simple professional use tests that deliver fast and accurate results in both clinical and community settings. In 2014, AtomoRapid HIV won Best in Show at the Medical Device Excellence Awards (MDEA) and Atomo was named Australian Emerging Company of the Year for 2014 by Johnson & Johnson Innovation.
Atomo is committed to increasing the early detection and ongoing treatment of infectious and chronic diseases by making testing safer, more accurate and more accessible.
Visit our website, www.atomodiagnostics.com, for more information on our company and products.
Atomo Diagnostics was established to capitalise on a core belief that healthcare products offering significantly improved levels of convenience, simplicity and user experience are disproportionately disruptive and have the potential to be very successful commercial market entrants.
In 2013, Atomo introduced AtomoRapid, a range of safe, simple professional use tests that deliver fast and accurate results in both clinical and community settings. In 2014, AtomoRapid HIV won Best in Show at the Medical Device Excellence Awards (MDEA) and Atomo was named Australian Emerging Company of the Year for 2014 by Johnson & Johnson Innovation.
Atomo is committed to increasing the early detection and ongoing treatment of infectious and chronic diseases by making testing safer, more accurate and more accessible.
Visit our website, www.atomodiagnostics.com, for more information on our company and products.
Location: Australia, New South Wales, Sydney
Employees: 11-50
Total raised: $10.86M
Founded date: 2010
Investors 3
| Date | Name | Website |
| - | Alium Capi... | aliumcap.c... |
| - | Sydney Ang... | sydneyange... |
| - | TEN13 | ten13.vc |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 15.06.2017 | - | $1.4M | - |
| 12.08.2016 | - | $3.46M | - |
| 01.02.2016 | - | $6M | - |
Mentions in press and media 5
| Date | Title | Description |
| 03.04.2020 | Medtech Atomo Diagnostics lands massive COVID-19 deal, closes $30 million raise early ahead of IPO | Rapid blood test startup Atomo Diagnostics is playing its part in the fight against coronavirus, signing a deal with French diagnostics company, NG Biotech, to supply up 2.465 million of its rapid, blood-based COVID-19 tests in 2020. The sa... |
| 28.10.2016 | Sydney HIV self testing startup Atomo Diagnostics awarded $3.6 million grant from Bill & Melinda Gates Foundation | Sydney healthtech startup Atomo Diagnostics has been awarded a $3.6 million (US$2.6 million) grant from the Bill and Melinda Gates Foundation to assist in its mission to develop a next generation HIV self-test. The grant follows on from $4.... |
| 12.08.2016 | Atomo Diagnostics Secures A$4.5M in Funding | Atomo Diagnostics, a Sidney, Australia-based medical device company, raised A$4.5m in equity funding. Backers included New York-based Global Health Investment Fund (GHIF), as well as a company associated with former Managing Director and CE... |
| 11.08.2016 | Atomo Diagnostics Raises A$4.5M Funding from Global Health Investment Fund | SYDNEY--(BUSINESS WIRE)--Medical device innovator Atomo Diagnostics today announced it had raised A$4.5 million in new equity funding from a number of professional investors including the New York-based Global Health Investment Fund (GHIF),... |
| 01.02.2016 | Atomo Diagnostics Receives $6M Loan from Global Health Investment Fund | Atomo Diagnostics, a Sydney, Australia-based developer of innovative rapid diagnostic tests, received a $6m loan from The Global Health Investment Fund (GHIF). The company will use the funds to scale-up production operations, expand commerc... |